Boehringer Ingelheim Venture Fund
Corporate VCIngelheim am Rhein · Seed–Growth · 7 people tracked
Find your way into Boehringer Ingelheim Venture Fund
3,723 people in our graph share verified history with the Boehringer Ingelheim Venture Fund team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.
Source: firm website, verified Jul 31, 2026.
Team · 7 people
from curated
What they invest in
from 21 of 21 portfolio companiesBiotech ×17Healthtech ×13Medical Devices ×11Deep Tech ×8Digital Health ×8AI & Machine Learning ×6Consumer ×1Data & Infrastructure ×1
HQs:Germany×4United States×4Belgium×3France×2China×1United Kingdom×1
Investments · 21 tracked
founders shown can be your intro pathBy year:2026 · 12022 · 22021 · 42020 · 12018 · 19 dated
Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing.
BiotechDigital HealthHealthtechMedical DevicesTübingen, DE
Hubert Löwenheim(Founder / Board Member)
Co-investorsKfWCreathor VenturesLBBW Venture Capital GmbHEsperante Ventures
ArrePath is a biotechnology company that applies AI/ML to drug discovery and development.
AI & Machine LearningBiotechDeep Tech
Zemer Gitai(Founder and SAB Chair)Kevin Krause(President and Chief Executive Officer)
Co-investorsInnospark VenturesInsight Partners
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)inPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsAdBio partnersRoche Venture FundSunstone CapitalJDRF T1D Fund
Nuevocor is a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesSingapore, SG
Brian Burke(Co-Founder and Advisor)inMark Kay(Co-Founder and Advisor)Colin Stewart(Co-Founder and Advisor)Yann Chong Tan(Co-Founder and Advisor)inMonica Shah(Chief Medical Officer)inAl Gianchetti(Chief Executive Officer)in
Co-investorsAngelini VenturesKurma PartnersClavystBioHighlight CapitalSEEDS Capital
Obulytix develops Precision Lysin Therapeutics, a novel class of engineered biologics designed to target multidrug-resistant Gram-negative bacteria for severe bloodstream and lung infections.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesGhent, BE
Yves Briers(Scientific Founder)in
Co-investorsQbic Fund
Rewind Therapeutics is a biotech company focused on neurodegeneration and neuroimmune diseases, with leadership and scientific advisory expertise in drug discovery, clinical development, and translational research for conditions like multiple sclerosis and Alzheimer's disease.
BiotechDeep TechDigital HealthHealthtechMedical DevicesLeuven, BE
Jim Van Heusden(Executive Chair)Irene Knuesel(Chief Scientific Officer)Christophe Van Vaeck(Chief Financial Officer)Ricardo Hermosilla(Head of Translational Medicine)Stephen Burbidge(VP Preclinical Drug Development)
Co-investorsPMVM VenturesSunstone Capital
Tacalyx develops novel anticancer therapeutics that target Tumor-Associated Carbohydrate Antigens (TACAs), including antibody-drug conjugate programs.
BiotechDeep TechMedical DevicesBerlin, DE
Peter Seeberger(Co-founder (Prof. Dr.))Oren Moscovitz(CSO & Co-founder)
Co-investorsCreathor VenturesKurma PartnerscoparionThuja CapitalApollo Health Ventures
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)inChristian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)in
Co-investorsEMBL VenturesGimvBioMedPartnersEpidarex Capital
Abalos Therapeutics develops immunotherapy treatments using arenavirus-based approaches for cancer.
BiotechHealthtech
Co-investorsVentura BioMed InvestorsApollo Health Ventures
Asgard provides sales intelligence and intent detection data to B2B companies, identifying qualified prospects and their specific needs for targeted sales outreach and account-based marketing campaigns.
AI & Machine LearningData & InfrastructureEnterprise SoftwareSales TechParis, FR
Co-investorsTechstarsIndustrifondenNovo HoldingsRobot Ventures
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical DevicesLund, SE
Cristiana Pires(Co-founder and CEO)inFábio Rosa(Co-founder and VP of Research)inFilipe Pereira(Co-founder and Head of Innovation)in
Co-investorsIndustrifondenLU InnovationNovo Holdings
C-mo develops an automated wearable device that records and analyzes cough patterns in real-time for continuous patient monitoring.
Digital HealthHealthtechMedical DevicesCaparica, PT
Co-investorsNovalis BiotechPortugal Ventures
Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAMR Action FundNCL Technology Ventures Ltd.
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.
BiotechDigital HealthHealthtechMedical DevicesNew York, US
David B. Klein(Founder and CEO)inDavid Klein(Executive Officer, Director)inRandall Stanicky(Executive Officer)in
BoardAlex Zisson(Director)Lee Shapiro(Director)inCris De Luca(Director)in
Co-investorsAccelmed PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersHealth Catalyst CapitalHikma VenturesSanofi Ventures+4 more
Delonix Group operates multiple hotel and experiential consumption brands across Asia-Pacific, leveraging AI and digital technology to drive member growth and innovation in hospitality.
ConsumerShenzhen, CN
郑南雁
Co-investorsINCE CapitalIDG CapitalZhenFund
Etherna is an RNA-LNP technology company that develops proprietary RNA chemistry and lipid nanoparticle delivery platforms for nucleic acid–based therapeutics, and partners with pharma and biotech organizations from early discovery through clinical development.
BiotechDeep TechMedical DevicesNiel, BE
Co-investorsFund+PMVEQT Life SciencesNovalis LifeSciencesPWV
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupCity Hill VenturesDelos CapitalKorea Investment PartnersLumira VenturesLYZZ Capital+1 more
.jpeg){kind=logo}
Optina develops a retinal imaging and AI platform for diagnosing and managing Age-Related Macular Degeneration in eye care specialists and patients.
AI & Machine LearningDigital HealthMedical Devices
Co-investorsDigitalDx VenturesDesjardins CapitalHike VenturesZoic Capital
Refoxy is a science-driven company focused on drug discovery, medicinal chemistry, and bioinformatics.
BiotechDeep TechHealthtechLongevity
Victor Bustos(Co-Founder & CEO)inWolfgang Link(Scientific Co-founder & Advisor)inAndrew Pierce(Chief Science Officer)in
Co-investorsKorify CapitalApollo Health VenturesHTGF
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsDelos CapitalVivo CapitalAMR Action FundKorea Investment PartnersLilly Asia VenturesMatrix Capital Management+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Portfolio news
latest coverage across their companiesCentauri Therapeutics · centauritherapeutics.com · May 5, 2026
Click Therapeutics · mobihealthnews.com · Apr 17, 2026
Delonix · finance.yahoo.com · Feb 6, 2026
Asgard · phemex.com · Dec 8, 2025
Nuevocor · precisionmedicineonline.com · May 9, 2025
Frequently asked questions
- How many investments has Boehringer Ingelheim Venture Fund made?
- Boehringer Ingelheim Venture Fund has 21 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.
- What stage does Boehringer Ingelheim Venture Fund invest at?
- Boehringer Ingelheim Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Boehringer Ingelheim Venture Fund's typical check size?
- Boehringer Ingelheim Venture Fund typically writes checks of $16.2M.
- What sectors does Boehringer Ingelheim Venture Fund focus on?
- Boehringer Ingelheim Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Boehringer Ingelheim Venture Fund located?
- Boehringer Ingelheim Venture Fund is headquartered in Ingelheim am Rhein, DE.
Co-investors · 7
Insight Partners is an investment firm focused on accelerating revenue and profit growth in software companies, providing capital and operational support through its Insight Onsite team.
Innospark Ventures is an early-stage investor backing technical founders building AI-driven solutions across healthcare, life sciences, and enterprise.
The JDRF T1D Fund is a venture philanthropy investor focused on type 1 diabetes (T1D), backing companies developing disease-modifying therapies and cures for the condition.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
Playground Global is a venture capital firm that invests in deep tech companies built by scientists and engineers, spanning next-generation compute, automation, energy, and computational biology.
Distributed Ventures is an early-stage venture firm that leads Seed and Series A investments in companies innovating across the health, insurance, and wealth risk ecosystems.
Canada's leading digital health venture capital firm investing in early-stage and high-growth technology companies transforming healthcare delivery across North America. The firm provides capital alongside hands-on operational guidance, commercial introductions, and go-to-market strategy support.
Firms observed investing alongside Boehringer Ingelheim Venture Fund, from public investor directories. Shared companies are the overlap with Boehringer Ingelheim Venture Fund's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.